Clinical application of recombinant erythropoietin in the perioperative period.
Recombinant human erythropoietin (EPO) therapy as an alternative to allogenic blood transfusion has been studied extensively in the perisurgical period. The potential benefits of EPO in this setting are twofold; EPO enhances autologous blood collection in advance of elective surgery and stimulates erythropoiesis perioperatively. Clinical evidence of the role of EPO therapy in these settings to minimize allogenic blood exposure is presented.
Department of Medicine, Washington University School of Medicine, St. Louis, Missouri.
L T
LT
Goodnough
D001804:Blood Transfusion, Autologous; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007430:Intraoperative Care / Q000379:methods*; D008297:Male; D011994:Recombinant Proteins / Q000627:therapeutic use
D011994:Recombinant Proteins; D004921:Erythropoietin